Gas Exchange in Renal Failure SIR,-In their interesting paper (1 May, p. 244), Drs. M. J. Goggin and A. M. Joekes successfully lay emphasis on an already wellestablished point-namely that a rise in Paco2 may be accompanied by a rise in serum potassium. In addition, they do well to remind us that respiratory compensation for metabolic acidosis may be abolished under anaesthesia. These are important points well made.
However, I am fearful lest a casual reader of their paper may now think suxamethonium to be exonerated as a potential cause of hyperkalaemia in renal failure. As I believe this matter to be still sub judice, may I make the following observations. They No details of suxamethonium dosages are given, and intraoperative blood samples were drawn at least 30 minutes after induction of anaesthesia (with one exception). In normal man the rise in serum potassium after suxamethonium is probably dose-related. It is maximal at about 7 minutes post-injection and is of the order of 0.55 mEq/l after a 100 mg dose.' Thirty minutes after a 40 mg dose, however, one would not expect to detect this rise.
The brief repor,t by Powell and Golby2 of a study in rats strongly suggests that potassium release following suxamethonium is highly abnormal in acute renal failure. A fuller report of this study is in press. It has been shownS in burned patients that the rise in seruxn potassium after suxamethonium is exacerbated by any concomitant acute rise in Paco2. In contrast, when suxamethonium was not employed no rise in potassium levels were seen.
In conclusion, it seems that the relative importance of the administration of suxamethonium and of changes in acid/base status is not yet settled. It is likely that both, on occasions, are significant factors in the production of hyperkalaemia, and, they may well be additive. Human Growth Hormone SIR,-In your leading article on the structure of human growth hormone (1 May, p. 236) you conclude that it is unlikely to be made synthetically for human therapy for a long time to come. The structural evidence on which this conclusion was based was published between May 19661 and December 1970. 2 Present progress in peptide hormone chemistry is so rapid that records of the structure already need to be revised and your conclusion to be reviewed. This remarkable rate of advance is undoubtedly owing to the availability of automatic techniques. In addition to the methods for amino-acid analysis and peptide synthesis to which you refer automatic sequence determination is now practicable.34 Niall' has used it to re-examine the aminoterminal region of human growth hormone and found that a sequence of 15 aminoacids was misplaced in the structure reported by Li et al. Niall's revised structure shows that the sequence homology between human growth hormone and human placental lactogen is much closer than previously thought. At least two other important conclusions can be drawn.
(1) The work clearly illustrates some of the drawbacks of solid state synthesis discussed by Bayer et al. 6 and Rudihbger. 7 Li and Yamashiro had no reason to be surprised that their synthetic product had only 10%°b of the biological activity of the purest natural growth hormone, because it was impossible to know to what extent it might be contaminated with a host of error peptides. Each of these might perhaps differ from the intended sequence only by the absence of a single residue and be impossible to remove at the end of the synthesis.
(2) The very fact that material of unknown chemical purity synthesized according to the incorrect sequence had significant biological activity shows that structural integrity of the total growth hormone sequence cannot be required for it to exert its effect. This was pointed out by Niall and underlined editorially. 8 The results of attempts to synthesize active fragments and analogues of human growth hormone are awaited with the greatest interest and may shorten the requirement for growth hormone prepared from human pituitaries to which you refer. Jejunal pH and Folic Acid SER,-The criticism levelled by Dr. W. F. Doe and others (20 March, p. 669) at our paper on the "Effect of Intraluminal pH on th absorption of Pteroylmonoglutamic Acid" (16 January, p. 148) prompts us to clarify certain points raised in their letter.
At no stage was it suggested that alteration in the intraluminal pH is the' sole governing factor in folate deficiency states. Experimentally in the rat everted sac folic acid transport is pH dependent, such that a small change in pH from 6 5 to 7-0 will reduce folic acid transport by more than 50%.1 In certain chronic epileptics who had developed megaloblastic anaemia on anticonvulsants, intraluminal conditions conducive to folate malabsorption have been detected. Similar alkaline conditions have been found in some patients with adult coeliac disease who also had low serum folates. Since folate deficiency in man is complex in aetiology the finding of an alkaline jejunal pH represents only one possible contributory factor, and the effect of alkalinity could be overcome by high dietary intake or adequate therapeutic doses of folic acid.
Our paper contains no reference to the mechanism by which phenytoin produced an alkaline intrajejunal state. We favour a metabolic mechanism for the phenomenon, since only at the end of a 10-day period
